Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil

A. Guglielmi, S. Barni, A. Zaniboni, N. Pella, O. Belvedere, G. D. Beretta, F. Grossi, L. Frontini, F. Puglisi, R. Labianca, A. Sobrero

Research output: Contribution to journalArticle

Abstract

Building upon the concept of schedule-specific biochemical modulation of 5-fluorouracil (FU), which alternates bolus and continuous infusion (CI) FU, we have incorporated oxaliplatin (I-OHP) following the bolus part of the regimen to explore the activity of this new combination. Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15) → I-OHP + FU (days 2 and 16) (200, 85 and 600 mg m -2 respectively) followed by 3 weeks of CI FU (200 mg m-2 day-1) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m-2). After 1 week of rest, the second cycle was started. The treatment was continued until progression or patient's refusal. According to the intention-to-treat analysis on all 46 patients accrued, the response rate was 42% (95% CL = 28-55%), with three complete responses and 16 partial responses. The median overall survival was 15.9 months and the median progression-free survival 6.9 months. Toxicity was very mild, with the bolus part of the regimen more toxic than the infusional part (24 vs 7% of grade III-IV, respectively). This new combination of MTX → I-OHP-FU followed by FU CI is well tolerated, feasible and produces activity results similar to other more simple, but more toxic, regimens. Pros and cons of the different fluoropyrimidines-I-OHP combinations are discussed.

Original languageEnglish
Pages (from-to)1428-1433
Number of pages6
JournalBritish Journal of Cancer
Volume91
Issue number8
DOIs
Publication statusPublished - Oct 18 2004

Fingerprint

oxaliplatin
Methotrexate
Fluorouracil
Colorectal Neoplasms
Poisons
Intention to Treat Analysis
Leucovorin
Disease-Free Survival
Appointments and Schedules

Keywords

  • 5-fluorouracil
  • Chemotherapy
  • Colorectal cancer
  • Methotrexate
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. / Guglielmi, A.; Barni, S.; Zaniboni, A.; Pella, N.; Belvedere, O.; Beretta, G. D.; Grossi, F.; Frontini, L.; Puglisi, F.; Labianca, R.; Sobrero, A.

In: British Journal of Cancer, Vol. 91, No. 8, 18.10.2004, p. 1428-1433.

Research output: Contribution to journalArticle

Guglielmi, A, Barni, S, Zaniboni, A, Pella, N, Belvedere, O, Beretta, GD, Grossi, F, Frontini, L, Puglisi, F, Labianca, R & Sobrero, A 2004, 'Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil', British Journal of Cancer, vol. 91, no. 8, pp. 1428-1433. https://doi.org/10.1038/sj.bjc.6602176
Guglielmi, A. ; Barni, S. ; Zaniboni, A. ; Pella, N. ; Belvedere, O. ; Beretta, G. D. ; Grossi, F. ; Frontini, L. ; Puglisi, F. ; Labianca, R. ; Sobrero, A. / Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. In: British Journal of Cancer. 2004 ; Vol. 91, No. 8. pp. 1428-1433.
@article{5d2f7f8b970d486987ff880b86554bc7,
title = "Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil",
abstract = "Building upon the concept of schedule-specific biochemical modulation of 5-fluorouracil (FU), which alternates bolus and continuous infusion (CI) FU, we have incorporated oxaliplatin (I-OHP) following the bolus part of the regimen to explore the activity of this new combination. Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15) → I-OHP + FU (days 2 and 16) (200, 85 and 600 mg m -2 respectively) followed by 3 weeks of CI FU (200 mg m-2 day-1) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m-2). After 1 week of rest, the second cycle was started. The treatment was continued until progression or patient's refusal. According to the intention-to-treat analysis on all 46 patients accrued, the response rate was 42{\%} (95{\%} CL = 28-55{\%}), with three complete responses and 16 partial responses. The median overall survival was 15.9 months and the median progression-free survival 6.9 months. Toxicity was very mild, with the bolus part of the regimen more toxic than the infusional part (24 vs 7{\%} of grade III-IV, respectively). This new combination of MTX → I-OHP-FU followed by FU CI is well tolerated, feasible and produces activity results similar to other more simple, but more toxic, regimens. Pros and cons of the different fluoropyrimidines-I-OHP combinations are discussed.",
keywords = "5-fluorouracil, Chemotherapy, Colorectal cancer, Methotrexate, Oxaliplatin",
author = "A. Guglielmi and S. Barni and A. Zaniboni and N. Pella and O. Belvedere and Beretta, {G. D.} and F. Grossi and L. Frontini and F. Puglisi and R. Labianca and A. Sobrero",
year = "2004",
month = "10",
day = "18",
doi = "10.1038/sj.bjc.6602176",
language = "English",
volume = "91",
pages = "1428--1433",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil

AU - Guglielmi, A.

AU - Barni, S.

AU - Zaniboni, A.

AU - Pella, N.

AU - Belvedere, O.

AU - Beretta, G. D.

AU - Grossi, F.

AU - Frontini, L.

AU - Puglisi, F.

AU - Labianca, R.

AU - Sobrero, A.

PY - 2004/10/18

Y1 - 2004/10/18

N2 - Building upon the concept of schedule-specific biochemical modulation of 5-fluorouracil (FU), which alternates bolus and continuous infusion (CI) FU, we have incorporated oxaliplatin (I-OHP) following the bolus part of the regimen to explore the activity of this new combination. Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15) → I-OHP + FU (days 2 and 16) (200, 85 and 600 mg m -2 respectively) followed by 3 weeks of CI FU (200 mg m-2 day-1) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m-2). After 1 week of rest, the second cycle was started. The treatment was continued until progression or patient's refusal. According to the intention-to-treat analysis on all 46 patients accrued, the response rate was 42% (95% CL = 28-55%), with three complete responses and 16 partial responses. The median overall survival was 15.9 months and the median progression-free survival 6.9 months. Toxicity was very mild, with the bolus part of the regimen more toxic than the infusional part (24 vs 7% of grade III-IV, respectively). This new combination of MTX → I-OHP-FU followed by FU CI is well tolerated, feasible and produces activity results similar to other more simple, but more toxic, regimens. Pros and cons of the different fluoropyrimidines-I-OHP combinations are discussed.

AB - Building upon the concept of schedule-specific biochemical modulation of 5-fluorouracil (FU), which alternates bolus and continuous infusion (CI) FU, we have incorporated oxaliplatin (I-OHP) following the bolus part of the regimen to explore the activity of this new combination. Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15) → I-OHP + FU (days 2 and 16) (200, 85 and 600 mg m -2 respectively) followed by 3 weeks of CI FU (200 mg m-2 day-1) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m-2). After 1 week of rest, the second cycle was started. The treatment was continued until progression or patient's refusal. According to the intention-to-treat analysis on all 46 patients accrued, the response rate was 42% (95% CL = 28-55%), with three complete responses and 16 partial responses. The median overall survival was 15.9 months and the median progression-free survival 6.9 months. Toxicity was very mild, with the bolus part of the regimen more toxic than the infusional part (24 vs 7% of grade III-IV, respectively). This new combination of MTX → I-OHP-FU followed by FU CI is well tolerated, feasible and produces activity results similar to other more simple, but more toxic, regimens. Pros and cons of the different fluoropyrimidines-I-OHP combinations are discussed.

KW - 5-fluorouracil

KW - Chemotherapy

KW - Colorectal cancer

KW - Methotrexate

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=7944234918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944234918&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602176

DO - 10.1038/sj.bjc.6602176

M3 - Article

C2 - 15381935

AN - SCOPUS:7944234918

VL - 91

SP - 1428

EP - 1433

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -